Mar 28 |
RBC starts Jasper Therapeutics at outperform, cites market opportunity
|
Mar 21 |
Jasper Therapeutics to Participate in the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference
|
Mar 19 |
Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a SPOTLIGHT Clinical Study of Briquilimab in Chronic Inducible Urticaria
|
Mar 15 |
New Positive Data Presented on Briquilimab Conditioning in Patients with Fanconi Anemia
|
Mar 4 |
Jasper Therapeutics GAAP EPS of -$1.50 beats by $0.20
|
Mar 4 |
Jasper Therapeutics Reports Fiscal 2023 Financial Results and Recent Corporate Developments
|
Feb 26 |
Jasper Therapeutics to Present at the 43rd Annual TD Cowen Healthcare Conference
|
Feb 23 |
Jasper Therapeutics Presents Data from Preclinical Briquilimab Studies at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting
|
Feb 12 |
Over $15M Bet On Aon? Check Out These 3 Stocks Insiders Are Buying
|
Feb 7 |
Jasper Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Conference
|